Hereditary predisposition to cancer associated with BARD1 is a moderate-penetrance tumor susceptibility syndrome, primarily related to an increased risk of breast cancer. It is caused by heterozygous pathogenic variants in BARD1 and follows an autosomal dominant pattern. Reduction of its tumor suppressor function alters DNA repair and favors the accumulation of genomic changes that can initiate malignant transformation.
Hereditary cancer (BARD1 gene)
The BARD1 gene encodes a nuclear protein that forms a heterodimer with BRCA1. This complex participates in the repair of double-strand breaks through homologous recombination, in the protection of replication forks, and in the cellular response to DNA damage.
Pathogenic variants in BARD1 compromise the BRCA1-BARD1 complex and favor the accumulation of genetic alterations. The predisposition is autosomal dominant and presents incomplete penetrance: a carrier individual may not develop cancer, and each descendant has a 50% chance of inheriting the variant. Population studies indicate a moderate increase in breast cancer risk, close to double the baseline risk, although the absolute risk depends on family history and other modifiers. The association appears stronger for estrogen receptor-negative and triple-negative tumors. An increased risk of ovarian cancer has not been convincingly demonstrated; the relationship with other tumors is still under study.
Symptoms
Genetic predisposition does not produce symptoms by itself. Manifestations appear if a tumor develops and depend on its location and stage. Breast cancer can occur in adulthood, sometimes earlier than in the general population, with a nodule, changes in the skin or shape of the breast, nipple retraction, or abnormal discharge. Triple-negative tumors are overrepresented, although other subtypes may appear. Clinical presentation is variable, and many carriers never develop cancer.
Disease management
Currently, hereditary predisposition cannot be eliminated, but surveillance can facilitate early diagnosis. Genetic counseling and age- and personal/family history-adapted follow-up are recommended. Guidelines include clinical breast examination from age 25, annual mammography from age 40, and consideration of annual magnetic resonance imaging from that age or earlier depending on family history. Evidence is insufficient to systematically recommend risk-reducing mastectomy. Specific preventive measures for the ovary or other organs based solely on BARD1 are not indicated. Tumors are treated according to their type and stage; therapies targeting homologous recombination defects are still under investigation.
Genes analyzed
Bibliography
Clinical Genome Resource. BARD1-related cancer predisposition: Gene-Disease Validity and Clinical Actionability. ClinGen. 2024.
Dorling L, Carvalho S, Allen J, et al. Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. N Engl J Med. 2021;384(5):428-439.
Hu C, Hart SN, Gnanaolivu R, et al. A Population-Based Study of Genes Previously Implicated in Breast Cancer. N Engl J Med. 2021;384(5):440-451.
Ceppi I, Dello Stritto MR, Mütze M, et al. Mechanism of BRCA1-BARD1 function in DNA end resection and DNA protection. Nature. 2024;634:492-500.
